1448429-52-4

Upstream product

• 2644-82-8 6-(chloromethyl)quinoline 
• 1448429-61-5 6-{1-[(1R,4R)-4-(tert-butyldimethylsilyloxy)cyclohexyl]-1H-pyrazol-4-yl}-1H-indazole 
• 1257997-17-3 1-((1r,4r)-4-((tert-butyl dimethyl silyl)oxy)cyclo hexyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole 
• 79762-54-2 6-bromo-1H-indazole 

Downstream Products

• 1448429-53-5 1-(quinolin-6-ylmethyl)-6-[1-((1R,4R)-4-hydroxy-cyclohexyl)-1H-pyrazol-4-yl]-1H-indazole 

Relevant academic research and scientific papers

Indazoles as potential c-met inhibitors: Design, synthesis and molecular docking studies

Deregulation of the receptor tyrosine kinase c-Met has been implicated in several human cancers and is considered as an attractive target for small molecule drug discovery. In this study, a series of indazoles were designed, synthesized and evaluated as novel c-Met inhibitors. The results showed that the majority of the compounds exhibited significant inhibition on c-Met and compound 4d showed highest activity against c-Met with IC50 value of 0.17 μM in TR-FRET-based assay and IC50 value of 5.45 μM in cell-based assay as compared to other tested compounds. Molecular docking experiments verified the results and explained the molecular mechanism of pretty activities to c-Met.